Skip to main content
50°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Fulgent Genetics, Inc. - Common Stock
(NQ:
FLGT
)
17.73
-0.59 (-3.25%)
Streaming Delayed Price
Updated: 11:25 AM EDT, Apr 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Fulgent Genetics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025
April 10, 2025
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results
February 28, 2025
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025
February 06, 2025
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Reports Third Quarter 2024 Financial Results
November 08, 2024
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent to Participate in Upcoming Conferences
November 05, 2024
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1
October 31, 2024
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024
October 17, 2024
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Reports Second Quarter 2024 Financial Results
August 02, 2024
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024
July 11, 2024
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
June 03, 2024
From
Fulgent Pharma
Via
Business Wire
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
May 24, 2024
From
Fulgent Pharma
Via
Business Wire
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
May 14, 2024
From
Fulgent Pharma
Via
Business Wire
Fulgent Reports First Quarter 2024 Financial Results
May 03, 2024
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
April 11, 2024
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024
February 13, 2024
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference
November 14, 2023
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting
November 03, 2023
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Reports Third Quarter 2023 Financial Results
November 03, 2023
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting
October 25, 2023
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Genetics to Announce Third Quarter 2023 Financial Results on Friday November 3, 2023
October 17, 2023
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Reports Second Quarter 2023 Financial Results
August 04, 2023
From
Fulgent Genetics, Inc.
Via
Business Wire
Exagen Inc. Appoints Paul Kim to Board of Directors
July 24, 2023
From
Exagen Inc.
Via
GlobeNewswire
Fulgent Genetics to Announce Second Quarter 2023 Financial Results on Friday, August 4, 2023
July 18, 2023
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various Cancers
June 05, 2023
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting
May 18, 2023
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Reports First Quarter 2023 Financial Results
May 05, 2023
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Genetics to Announce First Quarter 2023 Financial Results on Friday May 5, 2023
April 20, 2023
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Reports Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023
From
Fulgent Genetics, Inc.
Via
Business Wire
Fulgent Genetics Launches New Beacon787 Expanded Carrier Screening Panel
February 28, 2023
From
Fulgent Genetics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
